Joan Manthis
Corporate Officer/Principal bei Bausch & Lomb (Australia) Pty Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Norbert Walther | M | - |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 15 Jahre |
Chris van Niekerk | M | - |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 17 Jahre |
Robert Rosewell Chai-Onn | M | 52 |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | - |
Howard Schiller | M | 61 |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | - |
Greg J. Minton | M | 61 |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 18 Jahre |
Ben Frewin | M | - |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | 18 Jahre |
Jamshed Ahmed | M | - |
Bausch & Lomb (Australia) Pty Ltd.
Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Thomas A. Shea | M | 64 |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
William T. Pappafotopoulos | M | - |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Thomas J. Wilson | M | - |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | 1 Jahre |
Pierre V. Trân | M | 64 |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Timothy Barberich | M | 76 |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Walter Piskorski | M | 75 |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Randall D. Marshall | M | - |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 7 | 50,00% |
Australien | 7 | 50,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Joan Manthis
- Persönliches Netzwerk